Cargando…

Clostridioides difficile, a New “Superbug”

Clostridioides difficile is a Gram-positive, spore-forming, anaerobic bacterium. The clinical features of C. difficile infections (CDIs) can vary, ranging from the asymptomatic carriage and mild self-limiting diarrhoea to severe and sometimes fatal pseudomembranous colitis. C. difficile infections (...

Descripción completa

Detalles Bibliográficos
Autores principales: Markovska, Rumyana, Dimitrov, Georgi, Gergova, Raina, Boyanova, Lyudmila
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10140992/
https://www.ncbi.nlm.nih.gov/pubmed/37110267
http://dx.doi.org/10.3390/microorganisms11040845
_version_ 1785033285676564480
author Markovska, Rumyana
Dimitrov, Georgi
Gergova, Raina
Boyanova, Lyudmila
author_facet Markovska, Rumyana
Dimitrov, Georgi
Gergova, Raina
Boyanova, Lyudmila
author_sort Markovska, Rumyana
collection PubMed
description Clostridioides difficile is a Gram-positive, spore-forming, anaerobic bacterium. The clinical features of C. difficile infections (CDIs) can vary, ranging from the asymptomatic carriage and mild self-limiting diarrhoea to severe and sometimes fatal pseudomembranous colitis. C. difficile infections (CDIs) are associated with disruption of the gut microbiota caused by antimicrobial agents. The infections are predominantly hospital-acquired, but in the last decades, the CDI patterns have changed. Their prevalence increased, and the proportion of community-acquired CDIs has also increased. This can be associated with the appearance of hypervirulent epidemic isolates of ribotype 027. The COVID-19 pandemic and the associated antibiotic overuse could additionally change the patterns of infections. Treatment of CDIs is a challenge, with only three appropriate antibiotics for use. The wide distribution of C. difficile spores in hospital environments, chronic persistence in some individuals, especially children, and the recent detection of C. difficile in domestic pets can furthermore worsen the situation. “Superbugs” are microorganisms that are both highly virulent and resistant to antibiotics. The aim of this review article is to characterise C. difficile as a new member of the “superbug” family. Due to its worldwide spread, the lack of many treatment options and the high rates of both recurrence and mortality, C. difficile has emerged as a major concern for the healthcare system.
format Online
Article
Text
id pubmed-10140992
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-101409922023-04-29 Clostridioides difficile, a New “Superbug” Markovska, Rumyana Dimitrov, Georgi Gergova, Raina Boyanova, Lyudmila Microorganisms Article Clostridioides difficile is a Gram-positive, spore-forming, anaerobic bacterium. The clinical features of C. difficile infections (CDIs) can vary, ranging from the asymptomatic carriage and mild self-limiting diarrhoea to severe and sometimes fatal pseudomembranous colitis. C. difficile infections (CDIs) are associated with disruption of the gut microbiota caused by antimicrobial agents. The infections are predominantly hospital-acquired, but in the last decades, the CDI patterns have changed. Their prevalence increased, and the proportion of community-acquired CDIs has also increased. This can be associated with the appearance of hypervirulent epidemic isolates of ribotype 027. The COVID-19 pandemic and the associated antibiotic overuse could additionally change the patterns of infections. Treatment of CDIs is a challenge, with only three appropriate antibiotics for use. The wide distribution of C. difficile spores in hospital environments, chronic persistence in some individuals, especially children, and the recent detection of C. difficile in domestic pets can furthermore worsen the situation. “Superbugs” are microorganisms that are both highly virulent and resistant to antibiotics. The aim of this review article is to characterise C. difficile as a new member of the “superbug” family. Due to its worldwide spread, the lack of many treatment options and the high rates of both recurrence and mortality, C. difficile has emerged as a major concern for the healthcare system. MDPI 2023-03-26 /pmc/articles/PMC10140992/ /pubmed/37110267 http://dx.doi.org/10.3390/microorganisms11040845 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Markovska, Rumyana
Dimitrov, Georgi
Gergova, Raina
Boyanova, Lyudmila
Clostridioides difficile, a New “Superbug”
title Clostridioides difficile, a New “Superbug”
title_full Clostridioides difficile, a New “Superbug”
title_fullStr Clostridioides difficile, a New “Superbug”
title_full_unstemmed Clostridioides difficile, a New “Superbug”
title_short Clostridioides difficile, a New “Superbug”
title_sort clostridioides difficile, a new “superbug”
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10140992/
https://www.ncbi.nlm.nih.gov/pubmed/37110267
http://dx.doi.org/10.3390/microorganisms11040845
work_keys_str_mv AT markovskarumyana clostridioidesdifficileanewsuperbug
AT dimitrovgeorgi clostridioidesdifficileanewsuperbug
AT gergovaraina clostridioidesdifficileanewsuperbug
AT boyanovalyudmila clostridioidesdifficileanewsuperbug